ORIC Pharmaceuticals, Inc. (ORIC)

$4.4

-0.08 (-1.79%)
Rating:
Recommendation:
-
Symbol ORIC
Price $4.4
Beta 2.362
Volume Avg. 0.50M
Market Cap 173.704M
Shares () -
52 Week Range 2.62-26.7
1y Target Est -
DCF Unlevered ORIC DCF ->
DCF Levered ORIC LDCF ->
ROE -37.87% Strong Sell
ROA -37.04% Strong Sell
Operating Margin -
Debt / Equity 8.69% Neutral
P/E -
P/B 0.69 Buy
Annual
Quarter

Earnings

Consensus EPS

Upgrades & Downgrades

Latest ORIC news


Dr. Jacob M. Chacko M.B.A., M.D.
Healthcare
Biotechnology
NASDAQ Global Select

ORIC Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapies for treatment of cancers in the United States. Its clinical stage product candidates include ORIC-533, an orally bioavailable small molecule inhibitor of CD73 being developed for resistance to chemotherapy- and immunotherapy-based treatment regimens; ORIC-944, an allosteric inhibitor of the polycomb repressive complex 2 for prostate cancer; and ORIC-114, a brain penetrant orally bioavailable irreversible inhibitor designed to selectively target epidermal growth factor receptor and human epidermal growth factor receptor 2 with high potency towards exon 20 insertion mutations. The company is also developing multiple discovery stage precision medicines targeting other cancer resistance mechanisms. It has a license and collaboration agreement with Voronoi Inc.; and a license agreement with Mirati Therapeutics, Inc. The company was incorporated in 2014 and is headquartered in South San Francisco, California.